Information de reference pour ce titreAccession Number: | 01817247-200603000-00018.
|
Author: | DELAUNOIT, THIERRY *; LIMBURG, PAUL J. ++; GOLDBERG, RICHARD M. *; LYMP, JAMES F. [S]; LOFTUS, EDWARD V. JR ++,*
|
Institution: | (*)Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota (++)Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota ([S])Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota
|
Title: | |
Source: | Clinical Gastroenterology & Hepatology. 4(3):335-342, March 2006.
|
Abstract: | Background & Aims: Inflammatory bowel disease (IBD) is associated with an increased risk for colorectal cancer (CRC). However, the genetic, endoscopic, and histologic features of IBD-associated CRC differ from cancers that arise sporadically. The objectives of this study were to describe the clinicopathologic features of IBD-associated CRC and to compare survival rates between patients with IBD-associated CRC and patients with sporadic CRC.
Methods: There were 290 patients with IBD-associated CRC (241 with chronic ulcerative colitis [CUC] and 49 with Crohn's disease) and an equal number of age- and sex-matched sporadic CRC patients who were evaluated at the Mayo Clinic between 1976 and 1996. Medical records were reviewed retrospectively for demographic features, endoscopic and histologic characteristics, and vital status at the time of the last follow-up evaluation. The actuarial survival of each group was calculated by the Kaplan-Meier method. The influence of clinical features on survival was assessed using Cox proportional hazards regression modeling.
Results: The median age at diagnosis of IBD-related CRC was 48 years. Fifty-five percent of IBD-related tumors were distal to the splenic flexure compared with 78% of sporadic tumors. During a median follow-up period of 5 years, 163 IBD-associated CRC patients died (56%), compared with 164 sporadic CRC patients (57%). The 5-year survival rates were 54% in the IBD-CRC subgroup vs 53% in the sporadic CRC subgroup (P = .94, log-rank).
Conclusions: CUC-related CRC is diagnosed at a relatively young age, and IBD-related tumors tend to be distributed more evenly across the colorectum than sporadic tumors. The survival rates for IBD-associated and sporadic CRC were similar.
(C) 2006Elsevier, Inc.
|
References: | 1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease. incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
2. Eaden JA, Mayberry JF. Colorectal cancer complicating ulcerative colitis. a review. Am J Gastroenterol. 2000;95:2710-2719.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis. a meta-analysis. Gut. 2001;48:526-535.
4. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356-1362.
5. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997;41:522-525.
6. Jayaram H, Satsangi J, Chapman RW. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis. fact or fiction? Gut. 2001;48:430-434.
7. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD. a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91-96.
8. Harpaz N, Peck AL, Yin J, et al. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol. 1994;25:1069-1074.
9. Fogt F, Vortmeyer AO, Goldman H, et al. Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Hum Pathol. 1998;29:131-136.
10. Kern SE, Redston M, Seymour AB, et al. Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology. 1994;107:420-428.
11. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene. an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107:369-378.
12. Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis. a cancer-prone chronic inflammatory disease. Cancer Res. 2000;60:3333-3337.
13. Burmer GC, Levine DS, Kulander BG, et al. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology. 1990;99:416-420.
14. Hughes RG, Hall TJ, Block GE, et al. The prognosis of carcinoma of the colon and rectum complicating ulcerative colitis. Surg Gynecol Obstet. 1978;146:46-48.
15. van Heerden JA, Beart RW Jr. Carcinoma of the colon and rectum complicating chronic ulcerative colitis. Dis Colon Rectum. 1980;23:155-159.
16. Ritchie JK, Hawley PR, Lennard-Jones JE. Prognosis of carcinoma in ulcerative colitis. Gut. 1981;22:752-755.
17. Lavery IC, Chiulli RA, Jagelman DG, et al. Survival with carcinoma arising in mucosal ulcerative colitis. Ann Surg. 1982;195:508-512.
18. Gyde SN, Prior P, Thompson H, et al. Survival of patients with colorectal cancer complicating ulcerative colitis. Gut. 1984;25:228-231.
19. Sugita A, Greenstein AJ, Ribeiro MB, et al. Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. Ann Surg. 1993;218:189-195.
20. Aarnio M, Mustonen H, Mecklin JP, et al. Prognosis of colorectal cancer varies in different high-risk conditions. Ann Med. 1998;30:75-80.
21. Heimann TM, Oh SC, Martinelli G, et al. Colorectal carcinoma associated with ulcerative colitis. a study of prognostic indicators. Am J Surg. 1992;164:13-17.
22. Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn's disease and cancer. N Engl J Med. 1973;289:1099-1103.
23. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet. 1990;336:357-359.
24. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease. follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004;19:287-293.
25. Ribeiro MB, Greenstein AJ, Sachar DB, et al. Colorectal adenocarcinoma in Crohn's disease. Ann Surg. 1996;223:186-193.
26. Sobin LH, Wittekind C. TNM classification of malignant tumors 6th ed. New York: John Wiley & Sons; 2002.
27. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
28. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: J Wiley & Sons; 1980.
29. Cox D. Regression models and life-tables. J Royal Stat Soc. 1972;34:187-220.
30. Ries LAG, Eisner MP, Koser CL, et al. SEER cancer statistics review 1975. Bethesda, MD: National Cancer Institute; 2001.
31. Bargen J. Chronic ulcerative colitis associated with malignant disease. Arch Surg. 1928;17:561-576.
32. Slaney G, Brooke BN. Cancer in ulcerative colitis. Lancet. 1959;2:694-698.
33. Sloan WP Jr, Bargen JA, Gage RP. Life histories of patients with chronic ulcerative colitis. a review of 2,000 cases. Gastroenterology. 1950;16:25-38.
34. Shands WC, Dockerty MB, Bargen JA. Adenocarcinoma of the large intestine associated with chronic ulcerative colitis; clinical and pathologic features of 73 cases. Surg Gynecol Obstet. 1952;94:302-310.
35. Ohman U. Colorectal carcinoma in patients with ulcerative colitis. Am J Surg. 1982;144:344-349.
36. Johnson WR, McDermott FT, Hughes ES, et al. Carcinoma of the colon and rectum in inflammatory disease of the intestine. Surg Gynecol Obstet. 1983;156:193-197.
37. Connell WR, Talbot IC, Harpaz N, et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 1994;35:1419-1423.
38. Shelton AA, Lehman RE, Schrock TR, et al. Retrospective review of colorectal cancer in ulcerative colitis at a tertiary center. Arch Surg. 1996;131:806-811.
39. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis. implications for carcinogenesis and prevention. Gut. 1994;35:950-954.
40. Schneider A, Stolte M. Clinical and pathomorphological findings in patients with colorectal carcinoma complicating ulcerative colitis. Z Gastroenterol. 1993;31:192-197.
41. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis. a case-control study. Aliment Pharmacol Ther. 2000;14:145-153.
42. Rubin DT, Djordjevic A, Huo D, Yadrom N, et al. Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis. (abstr). Gastroenterology 2003;124(Suppl):A36.
43. van Staa TP, Card T, Leufkens HGM, Logan RF, et al. Prior aminosalicylate use and the development of colorectal cancer in inflammatory bowel disease (IBD): a large British epidemiological study. (abstr). Am J Gastroenterol 2003;98(Suppl):S244-S245.
44. Feig DI, Loeb LA. Oxygen radical induced mutagenesis is DNA polymerase specific. J Mol Biol. 1994;235:33-41.
45. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
|
Language: | English.
|
Document Type: | ORIGINAL ARTICLE.
|
ISSN: | 1542-3565
|
DOI Number: | https://dx.doi.org/10.1016/j.cgh...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|